title: Co-overexpression of bcl-2 and c-myc in uterine cervix carcinomas and premalignant lesions.
abstract: To establish the role of co-overexpression of bcl-2 and c-myc protooncogenes in uterine cervix carcinogenesis, we examined 138 tissue samples of low grade cervical squamous intraepithelial lesions (SIL), high grade SIL, portio vaginalis uteri (PVU) carcinoma in situ and PVU carcinoma invasive, stage IA-IIA (study group) and 36 samples without SIL or malignancy (control group). The expression of bcl-2 and c-myc was detected immunohistochemically using a monoclonal antibody. Fisher&rsquo;s exact test (P&lt;0.05) was used to assess statistical significance. Overexpression of bcl-2 was found to increase in direct relation to the grade of the cervical lesions. High sensitivity was of great diagnostic significance for the detection of these types of changes in the uterine cervix. On the basis of high predictive values it can be said that in patients with bcl-2 overexpression there is a great possibility that they have premalignant or malignant changes in the uterine cervix. Co-overexpression of bcl-2 and c-myc oncogenes was found only in patients with PVU invasive carcinoma (6/26-23.0%). Statistically significant difference was not found in the frequency of co-overexpression in patients with PVU invasive carcinoma in relation to the control group (Fisher&rsquo;s test; P=0.064). The method's sensitivity of determining these oncogenes with the aim of detecting PVU invasive carcinoma was 23%, while specificity was 72.2%. On the basis of high predictive values (100%), speaking in statistical terms, it can be concluded that all patients with co-overexpression of bcl-2 and c-myc oncogenes will have PVU invasive carcinoma. We confirmed in our research that co-overexpression of bcl-2 and c-myc oncogenes was increased only in PVU invasive carcinoma. However, a more extensive series of samples and additional tests are required to establish the prognostic significance of bcl-2 and c-myc co-overexpression in cervical carcinogenesis.
authors.affiliation: Department of Obstetrics andGynecology, University of Kragujevac, Serbia. protrka.zoran@gmail.com
authors.forename: Z
authors.initials: Z
authors.lastname: Protrka
authors.forename: S
authors.initials: S
authors.lastname: Arsenijevic
authors.forename: A
authors.initials: A
authors.lastname: Dimitrijevic
authors.forename: S
authors.initials: S
authors.lastname: Mitrovic
authors.forename: V
authors.initials: V
authors.lastname: Stankovic
authors.forename: M
authors.initials: M
authors.lastname: Milosavljevic
authors.forename: T
authors.initials: T
authors.lastname: Kastratovic
authors.forename: J
authors.initials: J
authors.lastname: Djuric
mesh_terms: D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D011230:Precancerous Conditions; D011379:Prognosis; D011446:Prospective Studies; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism*; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics / Q000378:metabolism*; D002583:Uterine Cervical Neoplasms / Q000503:physiopathology*
chemical_list: D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc